Adverse events during the induction phase
| Adverse event . | Lenalidomide (n = 37) Grade . | ||
|---|---|---|---|
| 3 . | 4 . | 5 . | |
| Alanine aminotransferase | 0 | 1 | 0 |
| Acute respiratory distress syndrome | 0 | 1 | 0 |
| Aspartate transaminase | 0 | 1 | 0 |
| Anorexia | 1 | 0 | 0 |
| Bilirubin | 1 | 0 | 0 |
| Cardiac ischemia/infarction | 0 | 0 | 1 |
| Cough | 1 | 0 | 0 |
| Creatinine | 3 | 0 | 0 |
| Dermatology-other | 1 | 0 | 0 |
| Diarrhea | 2 | 0 | 0 |
| Dyspnea | 1 | 0 | 1 |
| Fatigue | 9 | 2 | 0 |
| Febrile neutropenia | 12 | 2 | 1 |
| Gastrointestinal infection, 3-4 ANC: esophagus | 1 | 0 | 0 |
| Gastrointestinal infection, 3-4 ANC: gums | 1 | 0 | 0 |
| Hyperglycemia | 2 | 0 | 0 |
| Hypernatremia | 1 | 0 | 0 |
| Hypocalcemia | 1 | 2 | 0 |
| Hypokalemia | 3 | 0 | 0 |
| Hyponatremia | 1 | 0 | 0 |
| Lung infection, 3-4 ANC: lung | 4 | 1 | 0 |
| Muscle weakness: whole body | 2 | 1 | 0 |
| Nausea | 1 | 0 | 0 |
| Neuropathy-motor | 1 | 0 | 0 |
| Pneumonitis | 3 | 1 | 0 |
| Pulmonary-other | 1 | 0 | 1 |
| Rash | 2 | 0 | 0 |
| Renal failure | 1 | 0 | 0 |
| Skin infection, 3-4 ANC: lip/perioral | 1 | 0 | 0 |
| Skin infection, 3-4 ANC: skin | 1 | 0 | 0 |
| Vomiting | 1 | 0 | 0 |
| Maximum grade any adverse event, n | 20 | 5 | 4 |
| Adverse event . | Lenalidomide (n = 37) Grade . | ||
|---|---|---|---|
| 3 . | 4 . | 5 . | |
| Alanine aminotransferase | 0 | 1 | 0 |
| Acute respiratory distress syndrome | 0 | 1 | 0 |
| Aspartate transaminase | 0 | 1 | 0 |
| Anorexia | 1 | 0 | 0 |
| Bilirubin | 1 | 0 | 0 |
| Cardiac ischemia/infarction | 0 | 0 | 1 |
| Cough | 1 | 0 | 0 |
| Creatinine | 3 | 0 | 0 |
| Dermatology-other | 1 | 0 | 0 |
| Diarrhea | 2 | 0 | 0 |
| Dyspnea | 1 | 0 | 1 |
| Fatigue | 9 | 2 | 0 |
| Febrile neutropenia | 12 | 2 | 1 |
| Gastrointestinal infection, 3-4 ANC: esophagus | 1 | 0 | 0 |
| Gastrointestinal infection, 3-4 ANC: gums | 1 | 0 | 0 |
| Hyperglycemia | 2 | 0 | 0 |
| Hypernatremia | 1 | 0 | 0 |
| Hypocalcemia | 1 | 2 | 0 |
| Hypokalemia | 3 | 0 | 0 |
| Hyponatremia | 1 | 0 | 0 |
| Lung infection, 3-4 ANC: lung | 4 | 1 | 0 |
| Muscle weakness: whole body | 2 | 1 | 0 |
| Nausea | 1 | 0 | 0 |
| Neuropathy-motor | 1 | 0 | 0 |
| Pneumonitis | 3 | 1 | 0 |
| Pulmonary-other | 1 | 0 | 1 |
| Rash | 2 | 0 | 0 |
| Renal failure | 1 | 0 | 0 |
| Skin infection, 3-4 ANC: lip/perioral | 1 | 0 | 0 |
| Skin infection, 3-4 ANC: skin | 1 | 0 | 0 |
| Vomiting | 1 | 0 | 0 |
| Maximum grade any adverse event, n | 20 | 5 | 4 |
Grade 3 or higher nonhematologic adverse events. Events not likely or not related to treatment were excluded.